IMMUNITYBIO, INC. Interest Expense
IMMUNITYBIO, INC. (IBRX) reported Interest Expense of $60.89 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2026-02-23
- IMMUNITYBIO, INC. interest expense for the quarter ending 2025-12-31 was $14.84M, a 42.96% decline year-over-year.
- IMMUNITYBIO, INC. interest expense for the quarter ending 2025-09-30 was $15.26M, a 47.97% decline year-over-year.
- IMMUNITYBIO, INC. interest expense for the quarter ending 2025-06-30 was $15.47M, a 48.05% decline year-over-year.
- IMMUNITYBIO, INC. interest expense for the quarter ending 2025-03-31 was $15.31M, a 48.02% decline year-over-year.
- IMMUNITYBIO, INC. interest expense for fiscal 2025 was $60.89M, a 46.87% decline from fiscal 2024.
- IMMUNITYBIO, INC. interest expense for fiscal 2024 was $114.59M, a 11.07% decline from fiscal 2023.
- IMMUNITYBIO, INC. interest expense for fiscal 2023 was $128.85M, a 102.86% increase from fiscal 2022.
- IMMUNITYBIO, INC. interest expense for fiscal 2022 was $63.52M, a 327.74% increase from fiscal 2021.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $14.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $30.10M derived: sum of 2 quarters · filed 2026-02-23 | $45.57M derived: sum of 3 quarters · filed 2026-02-23 | $60.89M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | $15.26M 10-Q · filed 2025-11-05 | $30.73M derived: sum of 2 quarters · filed 2025-11-05 | $46.04M 10-Q · filed 2025-11-05 | $72.06M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2025-06-30 | $15.47M 10-Q · filed 2025-08-05 | $30.79M 10-Q · filed 2025-08-05 | $56.81M derived: sum of 3 quarters · filed 2026-02-23 | $86.13M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2025-03-31 | $15.31M 10-Q · filed 2025-05-12 | $41.33M derived: sum of 2 quarters · filed 2026-02-23 | $70.66M derived: sum of 3 quarters · filed 2026-02-23 | $100.44M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2024-12-31 | $26.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $55.34M derived: sum of 2 quarters · filed 2026-02-23 | $85.13M derived: sum of 3 quarters · filed 2026-02-23 | $114.59M 10-K · filed 2026-02-23 | $114.67M 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $29.32M 10-Q · filed 2025-11-05 | $59.11M derived: sum of 2 quarters · filed 2025-11-05 | $88.57M 10-Q · filed 2025-11-05 | $88.60M 10-Q · filed 2024-11-12 | $120.34M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-06-30 | $29.79M 10-Q · filed 2025-08-05 | $29.79M 10-Q · filed 2024-08-12 | $59.24M 10-Q · filed 2025-08-05 | $59.28M 10-Q · filed 2024-08-12 | $91.02M derived: sum of 3 quarters · filed 2026-02-23 | $126.04M derived: sum of 4 quarters · filed 2026-02-23 | ||
| 2024-03-31 | $29.46M 10-Q · filed 2025-05-12 | $29.48M 10-Q · filed 2024-05-09 | $61.23M derived: sum of 2 quarters · filed 2026-02-23 | $96.26M derived: sum of 3 quarters · filed 2026-02-23 | $128.49M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2023-12-31 | $31.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $66.80M derived: sum of 2 quarters · filed 2026-02-23 | $99.03M derived: sum of 3 quarters · filed 2026-02-23 | $128.85M 10-K · filed 2026-02-23 | $129.20M 10-K · filed 2024-03-19 | |||
| 2023-09-30 | $35.02M 10-Q · filed 2024-11-12 | $67.26M derived: sum of 2 quarters · filed 2024-11-12 | $97.07M 10-Q · filed 2024-11-12 | $125.63M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | $32.23M 10-Q · filed 2024-08-12 | $62.05M 10-Q · filed 2024-08-12 | $90.61M derived: sum of 3 quarters · filed 2025-03-03 | $107.38M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | $29.82M 10-Q · filed 2024-05-09 | $58.38M derived: sum of 2 quarters · filed 2025-03-03 | $75.14M derived: sum of 3 quarters · filed 2025-03-03 | $84.84M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | $28.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $45.33M derived: sum of 2 quarters · filed 2025-03-03 | $55.02M derived: sum of 3 quarters · filed 2025-03-03 | $63.52M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $16.76M 10-Q · filed 2023-11-09 | $26.46M derived: sum of 2 quarters · filed 2023-11-09 | $34.95M 10-Q · filed 2023-11-09 | $39.44M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-06-30 | $9.70M 10-Q · filed 2023-08-08 | $18.19M 10-Q · filed 2023-08-08 | $22.68M derived: sum of 3 quarters · filed 2024-03-19 | $26.29M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-03-31 | $8.49M 10-Q · filed 2023-05-11 | $12.98M derived: sum of 2 quarters · filed 2024-03-19 | $16.59M derived: sum of 3 quarters · filed 2024-03-19 | $20.17M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-12-31 | $4.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $8.10M derived: sum of 2 quarters · filed 2024-03-19 | $11.68M derived: sum of 3 quarters · filed 2024-03-19 | $14.85M 10-K · filed 2024-03-19 | ||||
| 2021-09-30 | $3.61M 10-Q · filed 2022-11-09 | $7.19M derived: sum of 2 quarters · filed 2022-11-09 | $10.36M 10-Q · filed 2022-11-09 | $13.20M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $3.58M 10-Q · filed 2022-08-08 | $6.75M 10-Q · filed 2022-08-08 | $9.58M derived: sum of 3 quarters · filed 2023-03-01 | $11.81M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $3.17M 10-Q · filed 2022-05-10 | $6.00M derived: sum of 2 quarters · filed 2023-03-01 | $8.23M derived: sum of 3 quarters · filed 2023-03-01 | $10.35M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | $2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $5.06M derived: sum of 2 quarters · filed 2023-03-01 | $7.18M derived: sum of 3 quarters · filed 2023-03-01 | $9.07M 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | $2.23M 10-Q · filed 2021-11-12 | $4.35M derived: sum of 2 quarters · filed 2021-11-12 | $6.24M 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | $2.12M 10-Q · filed 2021-08-12 | $4.01M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $1.89M 10-Q · filed 2021-05-14 | |||||||
| 2019-12-31 | $5.92M 10-K · filed 2022-03-01 | |||||||
| 2018-03-31 | $33.00K 10-Q · filed 2018-05-07 | $67.00K derived: sum of 2 quarters · filed 2018-05-07 | $460.00K derived: sum of 3 quarters · filed 2018-05-07 | $614.00K derived: sum of 4 quarters · filed 2018-05-07 | ||||
| 2017-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $427.00K derived: sum of 2 quarters · filed 2018-03-12 | $581.00K derived: sum of 3 quarters · filed 2018-03-12 | $618.00K 10-K · filed 2018-03-12 | ||||
| 2017-09-30 | $393.00K 10-Q · filed 2017-11-07 | $547.00K derived: sum of 2 quarters · filed 2017-11-07 | $584.00K 10-Q · filed 2017-11-07 | $621.00K derived: sum of 4 quarters · filed 2018-05-07 | ||||
| 2017-06-30 | $154.00K 10-Q · filed 2017-08-07 | $191.00K 10-Q · filed 2017-08-07 | $228.00K derived: sum of 3 quarters · filed 2018-05-07 | $257.00K derived: sum of 4 quarters · filed 2018-05-07 | ||||
| 2017-03-31 | $37.00K 10-Q · filed 2018-05-07 | $74.00K derived: sum of 2 quarters · filed 2018-05-07 | $103.00K derived: sum of 3 quarters · filed 2018-05-07 | $103.00K derived: sum of 4 quarters · filed 2018-05-07 | ||||
| 2016-12-31 | $37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $66.00K derived: sum of 2 quarters · filed 2018-03-12 | $66.00K derived: sum of 3 quarters · filed 2018-03-12 | $66.00K 10-K · filed 2018-03-12 | ||||
| 2016-09-30 | $29.00K 10-Q · filed 2017-11-07 | $29.00K derived: sum of 2 quarters · filed 2017-11-07 | $29.00K 10-Q · filed 2017-11-07 | $29.00K derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-06-30 | $0.00 10-Q · filed 2017-08-07 | $0.00 10-Q · filed 2017-08-07 | $0.00 derived: sum of 3 quarters · filed 2018-03-12 | $0.00 derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-08 | $0.00 derived: sum of 2 quarters · filed 2018-03-12 | $0.00 derived: sum of 3 quarters · filed 2018-03-12 | |||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $0.00 derived: sum of 2 quarters · filed 2018-03-12 | $0.00 10-K · filed 2018-03-12 | |||||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-10 | $0.00 10-Q · filed 2016-11-10 | ||||||
| 2014-12-31 | $471.00K 10-K · filed 2017-03-15 | |||||||
| 2013-12-31 | $463.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |